Clinical Trial

A Dose Randomization Study of Bulumtatug Fuvedotin in TNBC Patients Previously Treated With ADCs

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The goal of this clinical trial is to investigate if treatment with bulumtatug fuvedotin is effective in triple-negative breast cancer patients who have previously received treatment with an antibody-drug conjugates.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2025-03-26; most recent amendment 2026-03-16.
Status change: Not Yet Recruiting → Recruiting 2025-08-14
Trial Details
NCT Number NCT06908928
Lead Sponsor Mabwell (Shanghai) Bioscience Co., Ltd.
Conditions Triple Negative Breast Cancer
Enrollment 52 participants
Start Date 2025-08-11
Primary Completion 2027-05 (estimated)
Study Completion 2028-05 (estimated)
Updated on ClinicalTrials.gov 2026-03-17